Sponsored
Article Tools

Intercell starts a confirmatory clinical study using the Vaccine Enhancement

Published: May 4, 2011; 10:00 · (Vindobona)

Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches

Intercell starts a confirmatory clinical study using the Vaccine Enhancement / Picture: © Flickr

Today Intercell AG (VSE: ICLL) announced the start of a further trial in the field of pandemic Influenza, investigating Intercell's adjuvant patch (Vaccine Enhancement Patch - VEP) containing LT (a heat-labile toxin from E. coli) in combination with GSK's H5N1 pandemic antigen. This trial follows prior work with a non-GSK pandemic Influenza antigen carried out by Intercell under its…

This article includes a total of 337 words.

or Log In